retatrutide clinical trials safety efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 Retatrutide Weight Loss Results:Trial Data

It can only be accessed within authorised clinical trials

The statutory framework for compounding has always been limited, and as supply and access to approved products evolve, so too does the Agencys enforcement posture

Without an official SmPC, no confirmed refrigerated shelf-life or in-use storage period can be stated

Longest safety record

Resources on how to store peptides after reconstitution and how long peptides last in the fridge are relevant for anyone working with either compound in a research setting

Preclinical studies with GLP-1 agonists have raised questions about thyroid C-cell tumours in rodents, though this has not been confirmed in humans